ORKA

Business Context and Reporting Period

This Form 10-Q covers Hyseq, Inc. (Note: Metadata listed "Oruka Therapeutics," but the filing text identifies the registrant as Hyseq, Inc.) for the quarterly period ended June 30, 1999. Hyseq is a biotechnology company focused on gene discovery, sequencing technology (HyChip), and collaboration arrangements. The company is currently engaged in significant litigation regarding patent infringement with Affymetrix, Inc.

Key Financial Metrics

Material Changes vs. Prior Period

• Revenue Decline: Contract revenues decreased to $1.043 million for the quarter (from $2.680 million in Q2 1998) and $3.795 million for the six months (from $5.363 million in 1998). This was primarily due to the acceleration of collaboration efforts with Chiron Corporation into Q1 1999 to allow for production capacity expansion in Q2.
• Expense Fluctuations: Total operating expenses decreased to $5.925 million for the quarter (from $7.335 million in Q2 1998) due to lower material consumption costs. However, for the six-month period, expenses increased slightly to $13.715 million (from $13.505 million in 1998) driven by increased personnel costs, intellectual property investments, and facility expansion.
• Widening Loss: Net loss increased to $4.534 million for the quarter (from $3.918 million) and $9.136 million for the six months (from $6.606 million), reflecting lower revenues and higher operating costs.
• Cash Flow: Net cash used in operating activities increased to $9.959 million for the six months ended June 30, 1999, compared to $6.150 million in the prior year period, largely due to a reduction in accounts payable and higher operating expenses.

Guidance, Outlook, and Risks

• Liquidity Outlook: Management expects existing capital resources, anticipated revenues, and a $5.0 million asset-backed financing commitment (of which $1.2 million was drawn as of June 30) to fund operations through at least the first half of 2001.
• Revenue Expectations: Revenues from the Chiron collaboration are expected to increase to at least $1.3 million in Q3 1999 due to minimum funding requirements. Management notes that revenue recognition may fluctuate significantly quarter-to-quarter.
• Legal Contingencies: The company is involved in two consolidated lawsuits against Affymetrix alleging patent infringement regarding SBH technology. Affymetrix has filed counterclaims alleging invalidity and inequitable conduct. The outcome is uncertain, and the litigation has resulted in decreased legal activity pending a trial date.
• Year 2000 Compliance: The company believes its critical systems are Y2K compliant. Estimated costs for any required modifications are expected not to exceed $50,000.
• Risks: Future capital requirements depend on scientific progress, the ability to secure new collaboration partners, and the costs of enforcing patent rights. There is no assurance that additional funding will be available if needed.

Investor Verification Checklist

• Verify the status and potential financial impact of the ongoing patent litigation with Affymetrix, Inc.
• Confirm the stability of the collaboration agreement with Chiron Corporation and the timing of future milestone payments.
• Assess the sufficiency of the $36.9 million in cash and investments against the projected burn rate through 2001.
• Review the terms of the $5.0 million asset-backed financing commitment and any covenants associated with it.
• Monitor the progress of the HyChip universal sequencing chip product development and its potential for commercialization.